94. An JH, Blackwell TK (2003) SKN-1 links C. elegans mesendodermal specification to a conserved oxidative stress response. Genes Dev 17: 1882–1893. 95. Bowerman B, Eaton BA, Priess JR (1992) skn-1, a maternally expressed gene required to specify the fate of ventral blastomeres in the early C. elegans embryo. Cell 68: 1061–1075. 96. Kell A, Ventura N, Kahn N, Johnson TE (2007) Activation of SKN-1 by novel kinases in Caenorhabditis elegans. Free Radic Biol Med 43: 1560–1566. 97. Tullet JM, Hertweck M, An JH, Baker J, Hwang JY, et al. (2008) Direct inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in C. elegans. Cell 132: 1025–1038. 98. An JH, Vranas K, Lucke M, Inoue H, Hisamoto N, et al. (2005) Regulation of the Caenorhabditis elegans oxidative stress defense protein SKN-1 by glycogen synthase kinase-3. Proc Natl Acad Sci U S A 102: 16275–16280. 99. Park SK, Tedesco PM, Johnson TE (2009) Oxidative stress and longevity in Caenorhabditis elegans as mediated by SKN-1. Aging Cell 8: 258–269. 100. Dennis KE, Aschner JL, Milatovic D, Schmidt JW, Aschner M, et al. (2009) NADPH oxidases and reactive oxygen species at different stages of chronic hypoxia-induced pulmonary hypertension in newborn piglets. Am J Physiol Lung Cell Mol Physiol 297: L596–607. 101. Bonneh-Barkay D, Reaney SH, Langston WJ, Di Monte DA (2005) Redox cycling of the herbicide paraquat in microglial cultures. Brain Res Mol Brain Res 134: 52–56. 102. Gao HM, Liu B, Hong JS (2003) Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 23: 6181–6187. 103. Anantharam V, Kaul S, Song C, Kanthasamy A, Kanthasamy AG (2007) Pharmacological inhibition of neuronal NADPH oxidase protects against 1- methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells. Neurotoxicology 28: 988–997. 104. Thein MC, Winter AD, Stepek G, McCormack G, Stapleton G, et al. (2009) Combined extracellular matrix cross-linking activity of the peroxidase MLT-7 and the dual oxidase BLI-3 is critical for post-embryonic viability in Caenorhabditis elegans. J Biol Chem 284: 17549–17563. 105. Jain C, Yun M, Politz SM, Rao RP (2009) A pathogenesis assay using Saccharomyces cerevisiae and Caenorhabditis elegans reveals novel roles for yeast AP-1, Yap1, and host dual oxidase BLI-3 in fungal pathogenesis. Eukaryot Cell 8: 1218–1227. 106. Chavez V, Mohri-Shiomi A, Garsin DA (2009) Ce-Duox1/BLI-3 generates reactive oxygen species as a protective innate immune mechanism in Caenorhabditis elegans. Infect Immun 77: 4983–4989. 107. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, et al. (2008) Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson’s disease. Proc Natl Acad Sci U S A 105: 18578–18583. 108. Song N, Jiang H, Wang J, Xie JX (2007) Divalent metal transporter 1 up- regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx. J Neurosci Res 85: 3118–3126. 109. Zhang S, Wang J, Song N, Xie J, Jiang H (2008) Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))- induced apoptosis in MES23.5 cells. Neurobiol Aging. 110. Barzilai A, Melamed E (2003) Molecular mechanisms of selective dopaminergic neuronal death in Parkinson’s disease. Trends Mol Med 9: 126–132. 111. Betarbet R, Sherer TB, Greenamyre JT (2002) Animal models of Parkinson’s disease. Bioessays 24: 308–318. 112. Afonso-Oramas D, Cruz-Muros I, de la Rosa DA, Abreu P, Giraldez T, et al. (2009) Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson’s disease. Neurobiol Dis 36: 494–508. 113. McKinley ET, Baranowski TC, Blavo DO, Cato C, Doan TN, et al. (2005) Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons. Brain Res Mol Brain Res 141: 128–137. 114. Storch A, Ludolph AC, Schwarz J (2004) Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J Neural Transm 111: 1267–1286. 115. Prabhakaran K, Ghosh D, Chapman GD, Gunasekar PG (2008) Molecular mechanism of manganese exposure-induced dopaminergic toxicity. Brain Res Bull 76: 361–367. 116. Reaney SH, Smith DR (2005) Manganese oxidation state mediates toxicity in PC12 cells. Toxicol Appl Pharmacol 205: 271–281. 117. Milatovic D, Zaja-Milatovic S, Gupta RC, Yu Y, Aschner M (2009) Oxidative damage and neurodegeneration in manganese-induced neurotoxicity. Toxicol Appl Pharmacol 240: 219–225. 118. Milatovic D, Yin Z, Gupta RC, Sidoryk M, Albrecht J, et al. (2007) Manganese induces oxidative impairment in cultured rat astrocytes. Toxicol Sci 98: 198–205. 119. Olney JW, Zorumski CF, Stewart GR, Price MT, Wang GJ, et al. (1990) Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson’s and Huntington’s diseases. Exp Neurol 108: 269–272. 120. Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W (2006) The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 1762: 1068–1082. BLI-3/Dopamine-Dependent Mn-Induced Neurotoxicity 121. Berretta N, Freestone PS, Guatteo E, de Castro D, Geracitano R, et al. (2005) Acute effects of 6-hydroxydopamine on dopaminergic neurons of the rat substantia nigra pars compacta in vitro. Neurotoxicology 26: 869–881. 122. Wersinger C, Prou D, Vernier P, Sidhu A (2003) Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J 17: 2151–2153. 123. Kern CH, Stanwood GD, Smith DR () Preweaning manganese exposure causes hyperactivity, disinhibition, and spatial learning and memory deficits associated with altered dopamine receptor and transporter levels. Synapse 64: 363–378. 124. McDougall SA, Reichel CM, Farley CM, Flesher MM, Der-Ghazarian T, et al. (2008) Postnatal manganese exposure alters dopamine transporter function in adult rats: Potential impact on nonassociative and associative processes. Neuroscience 154: 848–860. 125. Bishop NA, Guarente L (2007) Two neurons mediate diet-restriction-induced longevity in C. elegans. Nature 447: 545–549. 126. Berkowitz LA, Hamamichi S, Knight AL, Harrington AJ, Caldwell GA, et al. (2008) Application of a C. elegans dopamine neuron degeneration assay for the validation of potential Parkinson’s disease genes. J Vis Exp. 127. Marvanova M, Nichols CD (2007) Identification of neuroprotective com- pounds of caenorhabditis elegans dopaminergic neurons against 6-OHDA. J Mol Neurosci 31: 127–137. 128. Springer W, Hoppe T, Schmidt E, Baumeister R (2005) A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress. Hum Mol Genet 14: 3407–3423. 129. Samann J, Hegermann J, von Gromoff E, Eimer S, Baumeister R, et al. (2009) Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J Biol Chem 284: 16482–16491. 130. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, et al. (2009) Nrf2- mediated neuroprotection in the MPTP mouse model of Parkinson’s disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A 106: 2933–2938. 131. Cuadrado A, Moreno-Murciano P, Pedraza-Chaverri J (2009) The transcrip- tion factor Nrf2 as a new therapeutic target in Parkinson’s disease. Expert Opin Ther Targets 13: 319–329. 132. van Muiswinkel FL, Kuiperij HB (2005) The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Curr Drug Targets CNS Neurol Disord 4: 267–281. 133. Park RM, Bowler RM, Eggerth DE, Diamond E, Spencer KJ, et al. (2006) Issues in neurological risk assessment for occupational exposures: the Bay Bridge welders. Neurotoxicology 27: 373–384. 134. McMillan G (2005) Is electric arc welding linked to manganism or Parkinson’s disease? Toxicol Rev 24: 237–257. 135. Sadek AH, Rauch R, Schulz PE (2003) Parkinsonism due to manganism in a welder. Int J Toxicol 22: 393–401. 136. Wennberg A, Iregren A, Struwe G, Cizinsky G, Hagman M, et al. (1991) Manganese exposure in steel smelters a health hazard to the nervous system. Scand J Work Environ Health 17: 255–262. 137. Anderson JG, Cooney PT, Erikson KM (2007) Inhibition of DAT function attenuates manganese accumulation in the globus pallidus. Environ Toxicol Pharmacol 23: 179–184. 138. Graumann R, Paris I, Martinez-Alvarado P, Rumanque P, Perez-Pastene C, et al. (2002) Oxidation of dopamine to aminochrome as a mechanism for neurodegeneration of dopaminergic systems in Parkinson’s disease. Possible neuroprotective role of DT-diaphorase. Pol J Pharmacol 54: 573–579. 139. Shen XM, Dryhurst G (1998) Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity. Chem Res Toxicol 11: 824–837. 140. Paris I, Martinez-Alvarado P, Cardenas S, Perez-Pastene C, Graumann R, et al. (2005) Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chem Res Toxicol 18: 415–419. 141. Zoccarato F, Toscano P, Alexandre A (2005) Dopamine-derived dopamino- chrome promotes H(2)O(2) release at mitochondrial complex I: stimulation by rotenone, control by Ca(2+), and relevance to Parkinson disease. J Biol Chem 280: 15587–15594. 142. Baez S, Linderson Y, Segura-Aguilar J (1995) Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase. Biochem Mol Med 54: 12–18. 143. Paris I, Cardenas S, Lozano J, Perez-Pastene C, Graumann R, et al. (2007) Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson’s disease. Neurotox Res 12: 125–134. 144. Zafar KS, Siegel D, Ross D (2006) A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol Pharmacol 70: 1079–1086. 145. Diaz-Veliz G, Mora S, Dossi MT, Gomez P, Arriagada C, et al. (2002) Behavioral effects of aminochrome and dopachrome injected in the rat substantia nigra. Pharmacol Biochem Behav 73: 843–850. 146. De Iuliis A, Burlina AP, Boschetto R, Zambenedetti P, Arslan P, et al. (2002) Increased dopamine peroxidation in postmortem Parkinsonian brain. Biochim Biophys Acta 1573: 63–67. 147. Galzigna L, Schiappelli MP, Rigo A, Scarpa M (1999) A rat brain fraction and different purified peroxidases catalyzing the formation of dopaminochrome from dopamine. Biochim Biophys Acta 1427: 329–336. PLoS Genetics | www.plosgenetics.org 17 August 2010 | Volume 6 | Issue 8 | e1001084